KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Depreciation & Amortization (CF) (2018 - 2025)

Historic Depreciation & Amortization (CF) for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $3.0 million.

  • Vir Biotechnology's Depreciation & Amortization (CF) rose 352.21% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 million, marking a year-over-year decrease of 2776.13%. This contributed to the annual value of $14.6 million for FY2024, which is 2515.04% down from last year.
  • Latest data reveals that Vir Biotechnology reported Depreciation & Amortization (CF) of $3.0 million as of Q3 2025, which was up 352.21% from $2.9 million recorded in Q2 2025.
  • Vir Biotechnology's 5-year Depreciation & Amortization (CF) high stood at $5.6 million for Q1 2023, and its period low was $1.3 million during Q1 2021.
  • In the last 5 years, Vir Biotechnology's Depreciation & Amortization (CF) had a median value of $2.9 million in 2024 and averaged $2.9 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 29732.21% in 2023, then tumbled by 3652.87% in 2025.
  • Vir Biotechnology's Depreciation & Amortization (CF) (Quarter) stood at $1.4 million in 2021, then skyrocketed by 68.0% to $2.4 million in 2022, then soared by 90.43% to $4.5 million in 2023, then tumbled by 35.57% to $2.9 million in 2024, then grew by 3.88% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $2.9 million for Q2 2025, and $2.9 million during Q1 2025.